Core Insights - The company is preparing for a busy 6 to 9 months ahead, focusing on key clinical developments and transitions [2] Group 1: Clinical Developments - The company plans to bring MAPT, its first CNS drug administered via subcutaneous injection, to the clinic [2] - Following MAPT, the company will introduce its first dimer, the PCSK9 APOC3 dimer, which is expected to be a significant tool against atherosclerotic cardiovascular disease (ASCVD) [2] Group 2: Regulatory and Data Milestones - A major event is the PDUFA date for plozasiran in November, marking a transition from an R&D-only company to one that is also commercial [3] - The company anticipates data releases for INHBE and ALK7 related to obesity, with additional ALK7 data expected in the first half of 2026, approximately 6 months behind INHBE in dosing [3]

Summary of Arrowhead Pharmaceuticals (ARWR) Conference Call Company Overview - **Company**: Arrowhead Pharmaceuticals (ARWR) - **Event**: 2025 Conference at Cantor's Global Healthcare Conference - **Date**: September 04, 2025 Key Priorities and Upcoming Events - **MAPT Clinical Trial**: Launching the first CNS drug administered via subcutaneous injection [3] - **PCSK9 ApoC3 Dimer**: Expected to enter the clinic, targeting ASCVD [4] - **Blazaran PDUFA Date**: Scheduled for November, marking a transition to a commercial company [4] - **Data Releases**: Anticipated data on MAPT and dimer by mid-2026 [5] Regulatory and Commercial Strategy - **Regulatory Interactions**: Positive discussions with regulators, no slowdown reported [6] - **Commercial Preparations**: Commercial team fully established and in training for FCS launch in November [7] Competitive Landscape - **SHTG Market**: Acknowledgment of competitor data, emphasizing the importance of education in the market [8] - **Pricing Strategy**: Discussion on pricing for Plazasiran, suggesting it may be higher than typical cardiovascular drugs due to its unique application [9][10] Clinical Trials and Data Expectations - **Shasta Trials**: Focused on triglyceride lowering, with Shasta-five designed to show effects on pancreatitis [11][12] - **Market Addressability**: Targeting patients with triglycerides above 800, estimated at one million in the U.S. [17][18] Product Differentiation - **Efficacy Comparison**: Plazasiran showed an 80% reduction in triglycerides compared to a competitor's 40% [23] - **Safety Profile**: Claims of superior safety and less frequent dosing compared to competitors [23] Obesity Portfolio - **Dual Targets**: ALK7 and Inhibin E targeting the activin pathway, with potential for both to advance based on clinical data [34] - **Market Positioning**: Potential for use as monotherapy or in combination with GLP-1s for obesity treatment [38] Business Development and Partnerships - **Partnership Strategy**: Focus on maintaining wholly owned assets while exploring partnerships for non-core assets [42][45] - **Recent Deal with Novartis**: $200 million upfront for a preclinical asset, indicating strong interest in CNS applications [46] Financial Outlook - **Cash Runway**: Sufficient cash to sustain operations until 2028, with expectations for further business development [59] Conclusion - Arrowhead Pharmaceuticals is positioned for significant developments in the CNS and metabolic disease markets, with a clear strategy for clinical trials, regulatory interactions, and commercial preparations. The company is focused on leveraging its innovative drug delivery platforms and maintaining a competitive edge through effective differentiation and strategic partnerships.